Wells Fargo analyst David Maris lowered his price target on Emergent BioSolutions to $61 and kept his Market Perform rating after its miss on Q1 revenue and earnings last week. The analyst also lowers his FY19 and FY20 EPS outlook by 7c and 41c to $3.01 and $3.27 respectively, reflecting the delays in its negotiations for a follow-on contact for its AMAC2000 Smallpox Vaccine and the management’s expectations for its FY19 earnings to be “even more heavily back half weighted.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.